Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nisoldipine
Drug ID BADD_D01570
Description Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Indications and Usage For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Marketing Status approved
ATC Code C08CA07
DrugBank ID DB00401
KEGG ID D00618
MeSH ID D015737
PubChem ID 4499
TTD Drug ID D0S5CU
NDC Product Code 0378-2097; 66993-473; 13672-042; 0378-2222; 0378-2099; 70515-503; 49706-1607; 13672-041; 13672-043; 0378-2223; 66993-472; 0378-2096; 0378-2098; 70515-501; 0378-2224; 66993-475; 70515-500
UNII 4I8HAB65SZ
Synonyms Nisoldipine | Bay K 5552
Chemical Information
Molecular Formula C20H24N2O6
CAS Registry Number 63675-72-9
SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001--Not Available
Acne23.02.01.001--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthma10.01.03.010; 22.03.01.002--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrioventricular block first degree02.03.01.004--
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blindness17.17.01.003; 06.02.10.003--Not Available
Blindness unilateral06.02.10.007; 17.17.01.016--Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardiac murmur13.14.01.001--Not Available
Cellulitis11.02.01.001; 23.11.02.004--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.005--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Colitis07.08.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene